I was looking for the timeframes involved between when the person realizes he/she is having an attack and the time that person has to do the injection. couldn't find that but found some light reading from Wikipedia. JUst some background noise for anyone new here or not familiar with these pens.
The devices contain a spring-loaded needle that exits the tip of the device (in some cases through a sterile membrane) and penetrates the recipient's skin, to deliver the medication via intramuscular injection.
Epinephrine autoinjectors contain a pre-determined dose of epinephrine, usually between 300 μg and 500 μg of active ingredient at a concentration of 1:1000. They typically contain more medication than the amount needed for a single dose, but any extra amount is not intended for use and is inaccessible without destroying the device. Manufacturers have also made pediatric dosed versions available at 150 μg of active ingredient. There was a version that contained two individual doses (in case a repeated application is required) previously sold under the trade name Twinject. The company that produced Twinject autoinjectors, Shionogi, announced that it was discontinuing Twinject effective March 30, 2012.
In 2010, European regulators approved a new epinephrine auto-injector made by ALK and sold under the brand name Jext.  The product was launched in the European Union in September 2011.
On August 13, 2012, the U.S. Food and Drug Administration (FDA) approved a new version of epinephrine auto-injector made by Intelliject and Sanofi called the Auvi-Q. It is rectangular in shape, 3.5 inches by 2 inches by 0.5 inch. It has a soundchip in it to give audio cues to a patient or caregiver to aid in the proper use of the device.
In January 2013, the UK MHRA approved Emerade (from Namtall AB), the first auto-injector fitted with 25mm needles to the 300μg and 500μg models.
In most countries, epinephrine is a prescription drug, and therefore obtaining the device requires a prescription from a doctor. However, in some jurisdictions, epinephrine autoinjectors are an over-the-counter drug and may be purchased from a pharmacy counter.
so in an emergency situatiion:
The subject, once realizing he's having a reaction, has to grab his epi-pen and prepare it for use.
Just how much time from the point of realization to the point when he's passing out or becoming immobile (for the act of using the pen), does the person have?
I'm kinda wondering just how much of an emergency situation this is.
Can't argue against this. Nicely said td.
I suppose the bureaucracy is at fault here. An attempt to slow or stop using the gov't to do it's thing:
Remember how the gov't works. It takes a whole room of people to say yes but it only takes one to say no. The serious: "covering ones #$%$" form of thought in the gov't is at play here. That's what Mylan is counting on.
So we are talking removing a cover on the needle end and then a thumb flip. It would seem obvious that the needle cover has to be removed before use and any one who gets a new drug or a new device (any reasonable person) would investigate how it works and what to do before using it and (any reasonable person) would do this before an emergency happens.
Shut up. If you're so sure that DRYS isn't in trouble. You wouldn't need to do this pumping to make yourself feel better.
In other words: you're insecure about this stock.
I have to agree with Camry here. (not that anyone gives a rats rear what I think) but ... really Nam... you know these issues are out there and the fact that ATRS did the (last) secondary at a 30 Mil Level is a persuasive data point. History (like the stock market) tends to repeat itself.
Well Then Nam... perhaps you should have said so. Failing to present both sides of known facts in your postings tend to make other people skeptical.
(who is always "Fair and balanced")
And the insurers will push (HARD) for discounts on TEVA's pen. regardless of how much they will save in the first place.
Just look at what happened to Otrexup.
HIs relevance is appropriate. There are many things you have ignored that will happen: competition (another pen from another company)
Market share will not hit 80 % (because of another pen from another company)
Then the lawsuits will happen.
Lets take that example of Otrexup with a pen, and it's a good analogy of what bumps likely will occur.
I'm going to get bookoo thumbs down on this but for CHRISSAKES !!!
Lets be more realistic:
Mylan will drop their price to stay competitive.
Teva will top out at 50% of Market share. (and it will take twice as long to get there)
Value to TEVA will be AT MOST: 450 Mil. at 50%MS
Include the cost of sales (production and it's overhead) and......
And the bottom line: ATRS at 7% = 25 M.
---- AND THAT"S BEING OPTIMISTIC ------
Then figure some other company will produce another generic just like Otrexup.
(always ready to burst a bubble)
Loko does good work. A little bit on the edgy side with his speculations but he does admit they are speculations. Wheniever you stick your neck out, someone will try to chop it off.
Now..... if we can only...... stop him from using...... those damn elipses................................. instead of a simple period at the end of his sentences........
it would help the read.
(smiles at loko)
ooooo right. I better take the advice from a num-nuts on a yahoo message board.!!
YIKES I BETTER SELL FAST !!!
I didn't read the article but the title tells me that the testosterone thwarts the *resistance* to the treatment of cancer.
Some of the things I've learned recently is that cancer cells can secrete a chemical that interferes with the immune systems attempts to kill it. Some treatments by Oncosec and Inovio companies have demonstrated a way to thwarts cancers ability to do this. Leaving the tumor open to attack. Right now, cancer treatment via immunology is HOT. And Oncosec (ONCS) has a method of drug delivery that pushed a chemical directly through the cell walls of the cancer, effectively stopping the tumor from preventing an attack by the T cells. The cancer has no defense.
THis treatment sounds similar (not the same). it's changing the tumor cells ability to fight back. It's not the testosterone that's killing the cancer.... it's the testosterones stopping the cancers **resistance** to the treatment.
I do NOT propose to understand much of what's going on with ONCOSEC. and the Issue of Porosity of the cell walls. but it seems to be working above expected trial results. Systemic responses have been seen that change non-repsonders to treatment; Into responders.
Go check it out.
"BDI is super low, oil is super low...and it will remain that way for months and months to come. "
You don't know that it will stay that way for months to come.
Link PLease? or some such info so we can read it for ourselves?
Cause I'm calling BS.
"is that $110m per q interest expense not real ?"
Silly... "everybody knows that".
Hint: it's priced in.